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Abstract - Carotid artery endarterectomy (CEA) is 
considered the gold standard for treatment of 
symptomatic and asymptomatic carotid disease. 
Carotid artery stenting (CAS) is a less invasive 
approach and therefore could be considered a viable 
alternative to CEA, especially in high-risk patients or 
those with relative contraindications to CEA (i.e. 
actinic stenosis, post-CEA restenosis, previous neck 
or tracheostomy surgery, contralateral laryngeal 
nerve paralysis, etc.). 
 Methods – The aim of this study is to evaluate the 
short- and medium-term outcomes of CAS 
performed with a single type of closed-cell stent 
design and distal filter protection by comparing the 
procedure with CEA based upon 3 endpoints: overall 
survival rate, stroke free survival rate and restenosis 
free survival rate. 
The same endpoints were also evaluated in 2 
different age groups, more and less than 70 years, to 
show possible age-based differences on outcomes. 
Among 105 patients (77 males, 28 females), 74 were 
submitted to CEA and 31 were subject to CAS.  
In all cases the same self-expanding stent with 
closed-cell design (XACT Carotid Stent, Abbott 
Vascular) and the same distal embolic protection 
device (Emboshield NAV, Abbott Vascular) were 
employed. 
Results – At 12 months, no statistically significant 
difference was observed in overall survival rates 
(CEA 93.2% vs CAS 93.5%, p=0.967) and restenosis 
free survival rates (CEA 94.5% vs CAS 96.8%, 
p=0.662). 
An increased stroke free survival rate was observed 
in the CEA group when compared to the CAS group 
(CEA 100.0% vs CAS 93.5%, p=0.028). 
The age-based endpoints didn’t show any significant 
difference. 
Conclusion - These results suggest that CEA still 
remains the gold standard of treatment for carotid 
stenosis given its greater efficacy in the prevention 
of stroke CAS. However, CAS could be considered 
as an alternative treatment to CEA to be used in 
select cases only. 
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I.  INTRODUCTION 
 
According to data from the World Health 
Organization (WHO), stroke is the third leading 
cause of death, the first major cause of physical 
disability, and the second cause of dementia1 in 
adults in the Western world. 
Severe carotid stenosis is the cause of about 20% of 
all strokes and therefore early diagnosis of lesions 
and suitable treatment can reduce the disability and 
mortality associated with stroke. 
A direct relationship exists between the rate of 
carotid artery stenosis and the risk of ipsilateral 
stroke2,3. Carotid revascularization by means of 
Carotid Endarterectomy (CEA) has been proven to 
be highly successful in reducing stroke incidence 
among patients with moderate-to-severe 
symptomatic carotid stenosis as well as amongst 
those with severe asymptomatic carotid stenosis4. 
However, some Randomized Controlled Trials 
(RCTs) reported a greater incidence of myocardial 
infarction with CEA than with the CAS5 procedure. 
For this reason, CAS is increasingly being adopted 
as an alternative procedure to CEA in patients with 
carotid stenosis. 
The aim of this study is to evaluate the outcomes 
associated with CAS carried out with a single type of 
closed-cell stent design and distal embolic protection 
device and to compare the results with those of the 
CEA procedure. Three endpoints were established 
and evaluated: overall survival rate, stroke free 
survival rate and restenosis free survival rate. 
 
II.  METHODS 
 
Between January 2013 and January 2016, we 
analyzed retrospectively 105 patients (77 males, 28 
females) with a mean age of 69.5 years (SD±9.34) 
who had been treated at our institute for 
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asymptomatic (62/105; 59%) and symptomatic 
(43/105; 41%) carotid stenosis.  
All patients were evaluated for the presence of the 
following risk factors for carotid steno-obstruction 
disease: smoke, hypertension, dyslipidemia, diabetes, 
coronary artery disease (CAD), chronic renal failure 
requiring dialysis treatment, and presence of 
ipsilateral neurological symptoms during the last 6 
months (fleeting amaurosis, TIA or minor stroke), 




table 1: distribution of risk factors for carotid stenosis in 
CEA and CAS groups. 
 
All carotid stenoses were evaluated by a duplex scan 
with the ECST method followed by a CT scan or 
MRI exam6-7. 
The entire cohort was divided into 2 groups 
according to the different carotid revascularization 
procedures employed: a CEA group and a CAS 
group. 
Before showing possible age-based differences on 
outcomes, both groups were analyzed on age using 
T-student method and then divided into 2 further 
groups each: more and less than 70 years CAS group 
and more and less than 70 years CEA group.  
 
 
The CEA Group 
CEA was performed under general anesthesia in 
74/105 patients (70.5%). An intravenous bolus of 
sodium heparin was administered (50-100 UI/Kg) 
before vessel clamping.   
A stump pressure method (SP) was used to evaluate 
the safety of carotid cross clamping, applying a 
temporary shunt to reduce the rate of cerebral 
ischemia when SP <40mmHg8. Standard CEA 
procedure was performed in 67/74 (90.54%) patients. 
A bovine pericardium patch (XenoSure) was applied 
in 14 cases (20.9%) while the arteriotomy was closed 
by direct running suture in 53 cases (79.1%).  
Application of a temporary shunt was necessary in 3 
cases (4.47%) due to low stump pressure value 
(SP=32 mmHg; SP=22 mmHg; SP=14 mmHg). 
An eversion CEA procedure was performed in 7/74 
patients (9.45%) to correct the concomitant 
tortuosity of the internal carotid artery. All patients 
received only a low dose of ASA (100 mg/die) or 
clopidogrel (75 mg/die) to reduce risk of post-
operative stroke and restenosis because due to a lack 
of evidence to support the use of dual antiplatelet or 





The CAS Group 
CAS was performed in 31/105 patients (29.5%). 
Three days before, all patients received a low dose of 
ASA (100 mg/die) and clopidogrel (75 mg/die). 
Endovascular procedures were performed under 
local anesthesia and the common femoral artery was 
used for vascular access in all patients.  
In only 2 cases (6.45%), after several unsuccessful 
attempts to catheterize the external carotid artery, 
was it necessary to convert the transfemoral access 
into a transcervical one.  
An intravenous bolus of sodium heparin was used in 
all patients during the procedure (50-100 UI/Kg). 
In all cases the same closed cell stent design was 
implanted (XACT Carotid Stent, Abbott Vascular) 
using the same distal embolic protection device 
(Emboshield NAV, Abbott Vascular) 10.  
The XACT Carotid Stent, available in both tapered 
and straight configurations, is a self-expanding 
nitinol stent with a closed cell design and dense 
scaffolding to minimize tissue and plaque prolapse. 
Its targeted radial strength generated by variable cell 
sizes offers the strength suited to anatomy and lesion 
location (figure 1a). 
The Emboshield NAV is a temporary percutaneous 
transluminal filtration system designed to capture 




Figure 1: a) XACT Carotid Stent in both tapered and 
straight configurations; b) Emboshield NAV filtration 
element (available from 
https://www.vascular.abbott/int/index.html) 
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Its filtration element consists of a nylon membrane 
with an internal nitinol frame with two proximal 
entry ports and multiple distal perfusion pores for 
enhanced capture efficiency and flow preservation 
(figure 1b)11.  
The mean stent diameter and length used on our 
patients was 8.0±1.3 mm and 38.4±3.7 mm, 
respectively.  
Atropine (0.5-1 mg e.v.) was administered only in 
patients with a heart rate ≤50 bpm to prevent risk of 
bradycardia before stent release. Post-dilatation was 
performed with a Maverick XL Monorail Balloon 
Catheter. 
All patients received dual antiplatelet therapy 
(clopidogrel 75 mg/die and ASA 100 mg/day) for at 
least 3 months after the procedure and then a single 
antiplatelet therapy (clopidogrel 75 mg/die or ASA 
100 mg/die) indefinitely.  
In patients with contralateral carotid occlusion, dual 
antiplatelet therapy was maintained lifelong. Follow-
up included a duplex scan after 1, 3, 6 months and 
every 12 months thereafter. 
 
III. CLINICAL CHARACTERISTICS 
 
Before performing statistical data analysis, all 
patients were assessed based upon their carotid 
stenosis risk factors: smoke, hypertension, 
dyslipidemia, type 1 and 2 diabetes, coronary artery 
disease (CAD), chronic renal failure requiring 
dialysis treatment, presence of ipsilateral 
neurological symptoms during the last 6 months 
(amaurosis fugax, TIA or minor stroke), contralateral 
occlusion (Table 1). As shown in Table 1, no single 
risk factor had a statistically significant difference in 
distribution in either group.  
All data were analyzed with SPSS 20.0 (IBM) to 
generate Kaplan-Meier survival curves and Log 





During the follow-up period 7 deaths (CEA 6.7%, 
CAS 6.4%), 2 strokes (CEA 0%, CAS 6.4%), and 5 
restenosis (CEA 5.4%, CAS 3.2%) occurred.   
No significant difference was found in the overall 
survival rate between the CEA and CAS groups 
(CEA 93.2% vs CAS 93.5%, p=0.967) (figure 2). 
The restenosis free survival also showed no 
significant differences between the two groups (CEA 
94.5% vs CAS 96.8%, p=0.622) (figure 3).  
On the contrary, the CEA group showed a higher 
stroke free survival rate than the CAS group (CEA 
100.0% vs CAS 93.5%, p=0.028) (figure 4).  
Furthermore, the only 2 strokes that occurred in the 
CAS group caused the death of the patients.  An 
onset of latero-cervical hematoma requiring urgent 
surgical treatment a few hours after surgery took 
place in only 2 cases (2.7%) among the CEA group. 
No other complications occurred in either group. 
The T-Student analysis on age didn’t show any 
significant difference between CEA and CAS groups 
(mean age: CEA 68.7±9.6 years vs CAS 71.5±8.3 
years, p=0.493). 
The age-based endpoints didn’t show any significant 
difference, as well (overall survival: more-70 years 
CEA 87.2% vs more-70 years CAS 90.5%, p>0.05; 
less-70 years CEA 100% vs less-70 years CAS 
100%, not applicable;   
stroke free survival: more-70 years CEA 100% vs 
more-70 years CAS 90.5%, p>0.05;  
less-70 years CEA 100% vs less-70 years CAS 
100%, not applicable;    
restenosis free survival: more-70 years CEA 97.4% 
vs more-70 years CAS 95.2%, p>0.05;  
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The biggest problem in CAS procedure is embolic 
risk, especially during stent release. Certainly, the 
introduction of Embolic Protection Devices (EPDs) 
has significantly reduced this risk as demonstrated 
by the SAPPHIRE12, CREST5 trials and two 
systematic reviews13-14.  However, not all types of 
commercially available carotid stents used in CAS 
procedures have the same impact on outcome. For 
example, the use of an open-cell stent design is 
associated with an increased 30-day stroke risk 
compared to a closed-cell stent design 15.     
Recent CAS observational retrospective studies 
suggest that the use of closed-cell stents may be 
associated with lower stroke and death after stenting, 
compared with open cell-stents, particularly in 
symptomatic patients or in cases of vulnerable 
plaques.  As well, the choice of a stent with a small 
free cell area can result in a significant decrease in 
post-procedural events15.   Studies have concluded 
that the rates of periprocedural complications with 
CAS and CEA procedures were relatively lower in 
centers with experienced operators and surgeons who 
had verifiable good outcomes16.  Over a 10-year 
period, both procedures were associated with stroke 
rates that were less than 7%17.  Instead, at centers 
where interventional and surgical experience could 
not be verified several retrospective studies of 
clinical databases showed higher rates of 
periprocedural stroke or death after stenting than 
those reported in the CREST and ICSS5 trials. 
Our own single center experience suggests that both 
CEA and CAS, when performed by experienced 
surgeons, are characterized by low prevalence of 
intraprocedural complications (CEA 2.7% vs 0% 
CAS). 
According to SICVE (Italian Society of Vascular and 
Endovascular Surgery) guidelines, CAS is preferred 
to CEA whenever there is at least one of the 
following conditions in a patient: severe cardiac or 
pulmonary comorbidity, previous radiotherapy or 
neck surgery, tracheostomy, too high carotid 
bifurcation, contralateral laryngeal paralysis and/or 
post-CEA restenosis18. Also, surgeons prefer CAS 
over CEA on all patients with contralateral carotid 
occlusion due to their low cerebral tolerance to the 
carotid clamp19-20. In our analysis, however, the 
stroke free survival rate in the CEA group was 
higher than in the CAS group (CEA 100.0% vs CAS 
93.5%, p=0.028). 
In addition, the strokes in CAS group, which were 
attributable to the cerebral distribution area of the 
treated carotid artery, occurred no later than 10 days 
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following procedure and all of them resulted in the 
patients’ death. 
Although our study being monocentric with a small 
number of patients, and all data analyzed is 
retrospective, a single type of stent and protective 
device was however used. The results of our data 
lead us to two important considerations: (1) most 
ischemic events after a CAS procedure can occur 
within the periprocedural period (first 30-days from 
procedure) due to the fact that they are caused by an 
intrinsic embolic risk of the CAS procedure. 
Although such risk has been strongly reduced thanks 
to the introduction of several EPDs, it is still a 
significant risk; (2) although stroke prevalence in the 
CAS group was not particularly high (6.45%), in our 
experience its effects were nonetheless devastating, 
directly leading to patient death; (3) in our humble 
experience, elderly patients with significant carotid 
stenosis have a similar risk of postoperative 
complications as the non-elderly population. 
Therefore, the high risk aspects of CAS should 
always be taken into consideration when choosing 
the most suitable type of carotid revascularization 
procedure for the patient. 
Based upon these 2 observations, we can conclude 
that CEA still remains the gold standard for 
treatment of carotid stenosis and that CAS with 
closed-cell stent can be considered as a viable 
alternative to CEA in selected cases only: severe 
cardiac and pulmonary comorbidity, previous 
radiotherapy or neck surgery, tracheostomy, post-
CEA or post-CAS restenosis, very high stenosis or 
bifurcation, laryngeal paralysis, contralateral 
occlusion and restenosis. Furthermore, the 
procedures should be performed in centers with 
documented experience and training program 
operators control where surgeons can choose the 
most efficient technique according based upon their 
experience, the patient’s clinical condition and 
prevailing risk factors.  
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